Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Vinorelbine and Capecitabine in Metastatic Breast Cancer
NCT00277069Phase 2Completed
- Sponsor
- The University of New Mexico
- Start
- May 2000
- Primary completion
- Mar 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in breast cancer, sponsored by The University of New Mexico. Primary endpoints: Objective Response Rate and Maximum Tolerated Dose. Started May 2000; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00277069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00277069.